• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Teligent Announces Fourth Quarter and Year End 2017 Results

    Gabrielle Lakusta
    Mar. 16, 2018 08:32AM PST
    Pharmaceutical Investing

    Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017. As quoted in the press release: For the year ending December 31, 2018, the Company expects total revenue in the range of $70-$78 million, EBITDA of $3-$6 million, gross margin in …

    Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2017.

    As quoted in the press release:

    For the year ending December 31, 2018, the Company expects total revenue in the range of $70-$78 million, EBITDA of $3-$6 million, gross margin in the range of 35-40%, and is planning to invest $13-$15 million in the R&D pipeline.

    “In the fourth quarter, the Company rebounded from a challenging third quarter and posted increased revenues for both our US portfolio of topical and injectable pharmaceutical products and our growing business in Canada” said Jason Grenfell-Gardner, President and Chief Executive Officer.

    Click here to read the full press release.

    pharmaceutical investingfinancial resultspharmaceutical productscanada
    The Conversation (0)

    Go Deeper

    AI Powered

    Tetraphase Reports Q4 and Full-Year 2019 Financial Results

    Teva Reports Fourth Quarter and Full Year 2019 Financial Results

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES